Emergent BioSolutions Appoints Interim CEO, Starts Permanent Search

Ticker: EBS · Form: 8-K · Filed: Apr 26, 2024 · CIK: 1367644

Emergent Biosolutions Inc. 8-K Filing Summary
FieldDetail
CompanyEmergent Biosolutions Inc. (EBS)
Form Type8-K
Filed DateApr 26, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.001, $399,753, $380,250, $373,761, $292,501
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, interim-ceo, board-of-directors

Related Tickers: EBS

TL;DR

Emergent BioSolutions CEO out, board chair Kramer steps in as interim, permanent search underway.

AI Summary

Emergent BioSolutions Inc. announced on April 23, 2024, the appointment of Robert G. (Bob) Kramer as Interim Chief Executive Officer, succeeding Paul F. McKinney. Kramer, who has been a board member since 2015, will also continue his role as Chairman of the Board. The company also reported that its Board of Directors has initiated a search for a permanent CEO.

Why It Matters

This leadership change signals a potential strategic shift for Emergent BioSolutions as they seek a new permanent CEO, which could impact the company's future direction and operational focus.

Risk Assessment

Risk Level: medium — Leadership changes can introduce uncertainty regarding strategy and execution, potentially impacting investor confidence and operational stability.

Key Players & Entities

  • Emergent BioSolutions Inc. (company) — Registrant
  • Robert G. (Bob) Kramer (person) — Interim Chief Executive Officer and Chairman of the Board
  • Paul F. McKinney (person) — Former Chief Executive Officer
  • April 23, 2024 (date) — Date of earliest event reported

FAQ

Who has been appointed as the Interim CEO of Emergent BioSolutions?

Robert G. (Bob) Kramer has been appointed as the Interim Chief Executive Officer.

Who did Robert G. Kramer succeed as CEO?

Robert G. Kramer succeeded Paul F. McKinney as CEO.

What other role does Robert G. Kramer hold?

Robert G. Kramer will continue in his role as Chairman of the Board.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on April 23, 2024.

What is the company initiating regarding its CEO position?

The company's Board of Directors has initiated a search for a permanent CEO.

Filing Stats: 885 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2024-04-26 16:30:22

Key Financial Figures

  • $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
  • $399,753 — ll pay an additional retention bonus of $399,753 to Mr. Lindahl, $380,250 to Ms. Fox, $3
  • $380,250 — ntion bonus of $399,753 to Mr. Lindahl, $380,250 to Ms. Fox, $373,761 to Ms. Glessner an
  • $373,761 — 53 to Mr. Lindahl, $380,250 to Ms. Fox, $373,761 to Ms. Glessner and $292,501 to Mr. Wil
  • $292,501 — o Ms. Fox, $373,761 to Ms. Glessner and $292,501 to Mr. Williams (together, the "Additio

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 10.1 Form of Amendment to Letter Agreement, dated April 23, 2024. 10.2 Form of Letter Agreement, dated July 26, 2023 (incorporated by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K filed on July 27, 2023). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: April 26, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.